Dr. Mario Gaudino

Women are at higher risk of death when undergoing heart bypass surgery than men. Researchers at Weill Cornell Medicine have determined that this disparity is mediated, to a large extent, by intraoperative anemia—the dilution of red blood cells during surgery.

A multi-institutional team of scientists led by Dr. Mario Gaudino, the Stephen and Suzanne Weiss Professor in Cardiothoracic Surgery and assistant dean for clinical trials at Weill Cornell Medicine, has been approved for a nearly $30 million funding award from the Patient-Centered Outcomes Research Institute (PCORI). 

Compared with men, women continue to have a roughly 30-40 percent higher risk of dying following coronary artery bypass surgery, according to a large study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

A new analysis shows that a combination of two anti-platelets drugs can benefit patients after the most common type of cardiac surgery — while also increasing the risk of potentially dangerous bleeding. 

A simple surgical technique during cardiac surgery was associated with a 56 percent reduction in the incidence of an irregular heart rhythm known as atrial fibrillation that can lead to stroke, with no added risks or side effects, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

For Dr. Mario Gaudino, being an excellent cardiothoracic surgeon and conducting clinical research to find new ways to improve patients’ outcomes have been two sides of the same coin since he was a medical student in Rome.

The risk of dying seven years after coronary artery bypass surgery was significantly lower in men receiving multiple bypass grafts rather than single grafts, but there was no apparent difference in mortality between these methods in women.

A long-standing debate among cardiologists comparing two common heart procedures is closer to being resolved.

One method for coronary artery bypass surgery is linked to a significantly lower risk of death, heart attack, or the need for a new surgery compared to the most commonly chosen one, according to an international study led by Weill Cornell Medicine and NewYork-Presbyterian heart surgeons.

The National Institutes of Health National Heart Lung and Blood Institute has awarded Weill Cornell Medicine investigators $4.2 million to compare quality of life outcomes in patients undergoing two different types of coronary artery bypass graft (CABG) surgery. 

In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.